TX-MAVENIR
27.8.2020 15:02:12 CEST | Business Wire | Press release
Vodafone UK has become the first UK mobile operator to switch on an OpenRAN 4G site, partnering with Mavenir , the industry's only end-to-end cloud-native Network Software Provider for Communications Service Providers (CSPs). This deployment in Wales is connecting Vodafone customers around the Royal Welsh Showground in Powys. Vodafone plans to use OpenRAN to more cost-effectively extend 4G services to rural communities and introduce new suppliers in the radio network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200827005273/en/
OpenRAN increases flexibility, agility, speed of rollout, and helps to decrease costs by using commercial off-the-shelf (COTS) hardware and new innovative virtualised and open solutions. OpenRAN is the foundational principle of open interfaces and product interoperability. It is based on initiatives from the Telecom Infra Project (TIP) and O-RAN Alliance , and will lead to networks that are more flexible, innovative and cost effective, and enables new suppliers to support mobile networks.
In this deployment, the RAN is also virtualised (vRAN). Virtualised RAN is the software application running on COTS that delivers cost effectiveness, increased flexibility and agility to the mobile operators, whilst providing one architecture for many different deployment scenarios.
Vodafone UK Chief Technology Officer Scott Petty said: “We are delighted to work together with Mavenir on the important milestone of the UK’s first live OpenRAN site. The introduction of the technology enables us to introduce new suppliers, such as Mavenir, giving us greater flexibility when rolling out our mobile network. We’re proud to be pioneering the development of OpenRAN and will be monitoring the performance of this first site.”
“We are proud to have achieved such a milestone with Vodafone and to provide innovative radio solutions in the market that transform the mobile network economics, while deploying technology with greater flexibility, greater efficiencies, and more agility as a full end-to-end Network Software Provider,” said Pardeep Kohli, President and CEO at Mavenir. “Mavenir is committed to bringing transformative innovation and technology to the telecommunications space and will continue to leverage our long history and experience in virtualised network solutions.”
About Vodafone UK:
Vodafone UK connects people, businesses and devices to help our customers benefit from digital innovation. Our services span mobile, fixed line connections, home and office broadband and the Internet of Things (IoT).
Having made the UK’s first mobile phone call and sent the first text message, Vodafone has a history as a tech pioneer. In 2018 we made the UK’s first live holographic call using 5G, and were first to start carrying live 5G traffic from a site in Salford, Greater Manchester. We now have 5G in more places than anyone else, with multiple locations now live across the UK and the rest of Europe.
Today we serve more than 18 million mobile and fixed line customers in the UK, with 4G network coverage at 99%. Our customers voted us the UK’s Best Mobile Network at the 2018 Trusted Reviews Awards – for the second year in a row. To help deliver Gigabit UK, our full-fibre broadband roll-out programme now covers 15 UK towns and cities through partnerships with CityFibre and Openreach.
Connectivity is at the heart of what we do as it gives us a huge opportunity for good. We are using our network, products, talents and technology to help society prosper and respond to significant social and environmental issues. Our free Digital Parenting magazine is helping families and schools across the UK to navigate the online world safely. Meanwhile, the Vodafone Foundation’s work with researchers at Imperial College is developing personalised cancer treatment using the processing power of smartphones.
We are part of Vodafone Group, one of the world’s largest technology communications companies, with mobile operations in 26 countries, partnerships with mobile networks in 55 more, and fixed broadband operations in 19 markets. As of 30 September 2019, Vodafone Group had approximately 625 million mobile customers, 27 million fixed broadband customers, and 22 million TV customers – including all of the customers in Vodafone’s joint ventures and associates.
For more information about Vodafone UK, please visit: www.vodafone.co.uk
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider for 4G and 5G, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom